Consensus guideline on the use of inhaler devices in asthma

Mike Thomas; H. Chrystyn; J. Leyshon; David Brendan Price; J. Roberts; R. Russell

Consensus guideline on the use of inhaler devices in asthma

Mike Thomas, H. Chrystyn, J. Leyshon, David Brendan Price, J. Roberts, R. Russell

Research output: Other contribution

Abstract

Asthma is a chronic respiratory disease characterised by variable
airflow limitation and airway hyper-responsiveness. It is highly
prevalent, affecting 5.2 million people in the UK.1 Effective inhaled
medications are available, which improve symptoms, pulmonary
function and quality of life and reduce exacerbations. However, for
many patients, symptoms remain poorly controlled.2,3 Incorrect use
of inhaler devices and/or non-compliance with inhaled medications are among several factors that compromise asthma management. 4,5 Furthermore, the result of inadequate asthma control has a significant impact on the overall costs of asthma. In the UK, the financial burden of this disease was estimated at almost £900 million,1 with lack of control responsible for up to 75% of costs.6

Original language	English
Type	Online supplement
Publisher	Medendium Group Publishing Ltd
Number of pages	8
Publication status	Published - 1 Jun 2007

Publication series

Name
Volume	33

Bibliographical note

This supplement has been supported by an educational grant from Teva UK Ltd. The views and opinions of contributors expressed in this publication are not necessarily those of Teva UK Ltd, Connectmedical or of Guidelines, its publisher, advisers and advertisers. No part of this publication may be reproduced in any form without the permission of the publisher.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{f66bf23896b0477da2f474173439a3c5,

title = "Consensus guideline on the use of inhaler devices in asthma",

abstract = "Asthma is a chronic respiratory disease characterised by variableairflow limitation and airway hyper-responsiveness. It is highlyprevalent, affecting 5.2 million people in the UK.1 Effective inhaledmedications are available, which improve symptoms, pulmonaryfunction and quality of life and reduce exacerbations. However, formany patients, symptoms remain poorly controlled.2,3 Incorrect useof inhaler devices and/or non-compliance with inhaled medications are among several factors that compromise asthma management. 4,5 Furthermore, the result of inadequate asthma control has a significant impact on the overall costs of asthma. In the UK, the financial burden of this disease was estimated at almost £900 million,1 with lack of control responsible for up to 75% of costs.6",

author = "Mike Thomas and H. Chrystyn and J. Leyshon and Price, {David Brendan} and J. Roberts and R. Russell",

note = "This supplement has been supported by an educational grant from Teva UK Ltd. The views and opinions of contributors expressed in this publication are not necessarily those of Teva UK Ltd, Connectmedical or of Guidelines, its publisher, advisers and advertisers. No part of this publication may be reproduced in any form without the permission of the publisher.",

year = "2007",

month = jun,

day = "1",

language = "English",

publisher = "Medendium Group Publishing Ltd",

type = "Other",

}

TY - GEN

T1 - Consensus guideline on the use of inhaler devices in asthma

AU - Thomas, Mike

AU - Chrystyn, H.

AU - Leyshon, J.

AU - Price, David Brendan

AU - Roberts, J.

AU - Russell, R.

N1 - This supplement has been supported by an educational grant from Teva UK Ltd. The views and opinions of contributors expressed in this publication are not necessarily those of Teva UK Ltd, Connectmedical or of Guidelines, its publisher, advisers and advertisers. No part of this publication may be reproduced in any form without the permission of the publisher.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Asthma is a chronic respiratory disease characterised by variableairflow limitation and airway hyper-responsiveness. It is highlyprevalent, affecting 5.2 million people in the UK.1 Effective inhaledmedications are available, which improve symptoms, pulmonaryfunction and quality of life and reduce exacerbations. However, formany patients, symptoms remain poorly controlled.2,3 Incorrect useof inhaler devices and/or non-compliance with inhaled medications are among several factors that compromise asthma management. 4,5 Furthermore, the result of inadequate asthma control has a significant impact on the overall costs of asthma. In the UK, the financial burden of this disease was estimated at almost £900 million,1 with lack of control responsible for up to 75% of costs.6

AB - Asthma is a chronic respiratory disease characterised by variableairflow limitation and airway hyper-responsiveness. It is highlyprevalent, affecting 5.2 million people in the UK.1 Effective inhaledmedications are available, which improve symptoms, pulmonaryfunction and quality of life and reduce exacerbations. However, formany patients, symptoms remain poorly controlled.2,3 Incorrect useof inhaler devices and/or non-compliance with inhaled medications are among several factors that compromise asthma management. 4,5 Furthermore, the result of inadequate asthma control has a significant impact on the overall costs of asthma. In the UK, the financial burden of this disease was estimated at almost £900 million,1 with lack of control responsible for up to 75% of costs.6

M3 - Other contribution

PB - Medendium Group Publishing Ltd

ER -

Consensus guideline on the use of inhaler devices in asthma

Abstract

Publication series

Bibliographical note

UN SDGs

Fingerprint

Cite this